HDL Therapy Under Development

The therapy is being developed by Lipid Sciences, Inc. (Pleasanton, CA, USA; www.lipidscience.com) along a parallel path with its viral immunotherapy platform. This new technology, focused on the removal of lipid coatings from viruses and other lipid-containing infectious agents, is called delipidation. Lipid Sciences has initiated a series of nonhuman primate studies to further validate the technology. The goal of these studies is the development of a therapeutic vaccine approach for use against HIV.

"Based on recent positive in vitro results from our HDL therapy development program, we believe that our practical, cost-effective proprietary delipidation process has the ability to boost HDL efficiency in reverse cholesterol transport and turn back the ‘cardiovascular clock' by reversing the build-up of fatty plaque in coronary arteries,” said Dr. S. Lewis Meyer, president and CEO of Lipid Sciences. The company is currently considering various initiatives, including evaluating recent third-party inquiries, to determine the best way to capitalize on the market opportunity represented by its HDL therapy.




Related Links:
Lipid Sciences